There is a lot of drug development based on that theory and most of it came up empty and the one that didn’t came up empty was Abuhelm which is widely seen as one of the worst FDA drug approvals of recent years.
There are actually three amyloid antibodies that have shown some success: aducanumab (Aduhelm), lecanemab (Leqembi), and donanemab. I think the FDA approval of aducanumab was absolutely the right decision, though it’s far from a miracle drug.
I spent about six months of my life buried in the Alzheimer literature. There’s a mountain of evidence for this hypothesis. Take a look at my previous comments if you’re curious.
In particular, Alzheimer’s disease is a dual prion disease (amyloid-β and tau), and there are numerous other known prion diseases.
See Nguyen et al (2021). Amyloid Oligomers: A Joint Experimental/Computational Perspective on Alzheimer’s Disease, Parkinson’s Disease, Type II Diabetes, and Amyotrophic Lateral Sclerosis and Shi et al (2021). Structure-based classification of tauopathies for some great detail on this.
There is a lot of drug development based on that theory and most of it came up empty and the one that didn’t came up empty was Abuhelm which is widely seen as one of the worst FDA drug approvals of recent years.
There are actually three amyloid antibodies that have shown some success: aducanumab (Aduhelm), lecanemab (Leqembi), and donanemab. I think the FDA approval of aducanumab was absolutely the right decision, though it’s far from a miracle drug.
I spent about six months of my life buried in the Alzheimer literature. There’s a mountain of evidence for this hypothesis. Take a look at my previous comments if you’re curious.